BioSpace News Archive

Cybin Inc. today announced the completion of dosing of the final cohort in its Phase 2 study of CYB003, a proprietary deuterated psilocybin analog program in development for the potential treatment of major depressive disorder (“MDD”).

HanchorBio Inc. today announced that the first patient has been dosed in a Phase 1, multi-regional, multi-center clinical trial (ClinicalTrials.gov ID: NCT05892718).

ImmPACT Bio USA , Inc. (“ImmPACT BIO”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate at the 2023 Cell & Gene Meeting on the Mesa, being held October 10-12, 2023.

Purple Biotech provides clinical updates from its dose escalation portion of the Phase 1/2 study of NT219, a first in class dual inhibitor of Insulin receptor substrate (IRS) 1/2 and Signal Transducer and Activator of Transcription 3 (STAT3) and provides its outlook for planning the next clinical development steps with NT219 for second-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head & Neck (R/M SCCHN).

FineHeart S.A announced today that it has received authorization from the SUKL (the Czech Republic State Institute for the Control of Medicinal Products) to carry out “A prospective, single arm, single center, First in Human Study to evaluate the safety and performance at 30 days of the FineHeart FLOWMAKER® in subjects with advanced heart failure.”

Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the third quarter 2023 after the close of trading on Tuesday, November 7.

Biohaven Ltd. announced the pricing of its underwritten public offering of 10,227,273 of its common shares at a price to the public of $22.00 per share.

Sanofi announces that it has entered into an agreement with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, to develop and commercialize the vaccine candidate for extraintestinal pathogenic E.coli developed by Janssen, currently in Phase 3.

Faron Pharmaceuticals Oy announces it will host a virtual call for investors to provide an update on the most recent Phase I/II BEXMAB data in acute myeloid leukemia and myelodysplastic syndrome on Wednesday, October 11 at 08.00 EST/13.00 BST/15.00 EEST.

Automata Technologies, a leading automation company powering life sciences labs, has raised $40m to accelerate its rapid growth and industry presence across the US, UK and EMEA.